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Brief Definitive Report 
CYCLOPHOSPHAMIDE-SENSITIVE T  LYMPHOCYTES 
SUPPRESS THE  IN  VIVO  GENERATION 
OF  ANTIGEN-SPECIFIC CYTOTOXIC  T  LYMPHOCYTES* 
BY M.  ROLLINGHOFF,  A.  STARZINSKI-POWITZ,  K.  PFIZENMAIER,  AND H.  WAGNER 
(From the Institut fiir Medizinische Mikrobiologie der Universitdt Mainz, Hochhaus 
Augustusplatz, 65 Mainz, Germany) 
Murine T lymphocytes sensitized in vitro against either allogeneic lympho- 
cytes or syngeneic hapten-conjugated lymphocytes do differentiate into highly 
effective cytotoxic T lymphocytes  (CTL) (1-3).  In vivo immunization of T lym- 
phocytes  to  the  same  antigens,  however,  results  in  the  generation  of only 
marginal cytotoxic activity (1, 4, 5). Recently we found that the weakness of in 
vivo  generated  cytotoxicity  is  not due to a  failure of antigen-induced  T-cell 
sensitization  but  rather  due  to  suppression  of the  in  vivo  differentiation  of 
sensitized CTL precursors into effective CTL (6). In keeping with this finding it 
was postulated that suppressor cells may regulate the in vivo differentiation of 
CTL. 
We now report,  that cyclophosphamide-sensitive T cells suppress the in vivo 
differentiation of antigen-specific CTL. Thus, pretreatment of mice with a single 
dose of cyclophosphamide (100 mg/kg) converts their state of low responsiveness 
to a state of high responsiveness. 
Materials and Methods 
Mice.  CBA/J, C3H, BALB/c, and C3H nu/nu mice from Bomholtgaard, Ry, Denmark, 8-12 wk 
of age, were used. 
Administration  of  Cyclophosphamide.  Cyclophosphamide  (Endoxan;  Asta-Werke, 
Brackwede, Germany) was dissolved in sterile saline immediately before use and injected by the 
intraperitoneal  (i.p.)  route  as  a  single  dose  in  graded  amounts  at  varying  intervals  before 
immunization. 
In Vivo Induction of BALB/c or TNP-Specific Cytotoxic  Lymphocytes.  The method used has 
been described  (5,  6).  In brief,  mice were  injected with 2  ×  107 allogeneic or TNP-conjugated 
syngeneic spleen cells into the hind foot pad. The TNP conjugation was performed as described (3, 
7). In brief, splenic lymphocytes were incubated in phosphate-buffered saline (PBS) containing 10 
mM trinitrobenzol sulfonic acid (TNBS) (Eastman Organic Chemicals Div., Eastman Kodak Co., 
Rochester, N. Y.). 3 days later the draining lymph nodes were removed and the cells obtained were 
tested for cytotoxic activity against either 51Cr-labeled P815  mastocytoma tumor cells or TNP- 
conjugated tipopolysaccharide (LPS)-induced syngeneic blast cells. 
Preparation of TNP Targets.  Replicate cultures ofsplenic lymphocytes (4 × 106) were cultured 
in the presence of 5 ~g LPS (Difco Laboratories,  Detroit, Mich.) over a  period of 48 h. The cells 
were harvested, labeled with [5~Cr]chromate and incubated for 10 min at 37°C in PBS containing 
10 mM TNBS.  The cells were washed and used as targets (3, 7). 
Cytotoxicity Assay.  Variable numbers of viable lymph node (LN) cells were incubated for 3 h 
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TABLE I 
The Effect of Pretreatment with Cyclophosphamide on the In 
Vivo Generation of TNP-Specific Cytotoxic T  Cells* 
Dose of cyclophosphamide ad- 
ministered i.p. at day 2 
* Specific lysis of TNP-conjugated CBA targets 
Cytotoxic activity  of  CBA LN cells  at  various intervals 
alter  immunization (days): 
2  3  4  5 
mg/k~ 
0  2  9  4  -1 
10  -2  5  3  0 
50  3  7  25  7 
100  5  29  42  11 
200  1  12  10  13 
* 2 Days  after cyclophosphamide  treatment,  CBA mice  were  injected  with 2  ×  107 TNP- 
conjugated syngeneic  spleen cells into the hind feet pad. At various intervals the draining LNs 
were removed and the cells were tested for cytotoxic activity against TNP-conjugated  LPS- 
induced syngeneic blast cells at an effector to target cell ratio of 30:1. Assay time of the ~Cr 
tests was 3 h, background lysis of the targets was less than 22%. 
with  a  constant  number  of 2  ×  104  51Cr-labeled  target  cells.  Percent  specific 51Cr  release  was 
calculated  (7). 
Preparation of Cell Suspensions  Used For Reconstitution Experiments.  Cortison-resistant  thy- 
mocytes  were  obtained  from  mice that  were  injected  i.p.  with  1.5  mg  cortisone  acetate  (Ciba- 
Geigy, Wehr,  Germany)  24 h  earlier. Bone marrow  cells and spleen cells were obtained according 
to  standard  procedures.  Enrichment  of splenic T  cells was  achieved  by  use  of the  nylon  wool 
column technique  as described (8), Enrichment  of splenic B  cells was done by the use of AKR anti- 
Thy 1.2 serum plus complement.  The antiserum  was raised and used as described previously (9). 
Results 
The data depicted in Table I show that CBA mice immunized in vivo by a local 
graft of TNP-conjugated syngeneic spleen cells (2 ×  107 ceils) do not generate a 
substantial amount of cytotoxic T effector cells (CTL) in the draining LN. This 
finding is in accordance with earlier reports (4, 6). Surprisingly however, CBA 
mice treated with cyclophosphamide 2 days before in vivo immunization  with 
trinitrophenylated  CBA cells did generate in vivo effectively TNP-specific CTL 
(Table I). Maximal specific cytolysis was observed 4 days after in vivo immuni- 
zation. While cyclophosphamide at a dose of 100 mg/kg had an optimal augment- 
ing effect, larger doses were considerably less efficient (Table I). Data given in 
Table II demonstrate that the cyclophosphamide-dependent augmenting  effect 
on the capacity of mice to generate in vivo CTL is not only a feature of the "TNP 
model," but applies also to the in vivo generation of alloantigen-reactive  CTL. 
As detailed in Table II, in the H-2 ~" anti-H-2 d system the optimal time point for 
the pretreatment  with cyclophosphamide was 2 days before in vivo immuniza- 
tion.  Drug application simultaneously with the alloimmunization  had no aug- 
menting effect on the differentiation of anti BALB/c CTL. Furthermore  it was 
noted that  the  effect of cyclophosphamide decreased with  an  increasing  time 
interval  between drug  administration  and  the  in vivo immunization,  2 days 
being optimal. 
The above results suggest that under normal in vivo conditions the stimula- 
tory potential  of both  allogeneic  lymphocytes and  TNP-conjugated  syngeneic 
lymphocytes is  suppressed by some unknown  mechanism  that  is sensitive to 
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TASLE II 
The Effect of Pretreatment with Cyclophosphamide of CBA Mice at 
Various Intervals on the In Vivo Generation of  H-2 d Specific Cytotoxic 
T  Cells* 
457 
Cyclophosphamide (100 mg/kg) ad- 
ministered i.p. at various intervals 
Cytotoxic activity of CBA LN cells 3 days aRer immunization 
% specific lysis of ~lCr-labeled targets 
P 815 (H-2 ¢)  EL 4 (H-2 ~) 
30:1  3:1  30:1  3:1 
days 
0  6  -1  4  1 
-2  52  24  11  -3 
-4  26  13  6  2 
-6  23  9  -2  0 
-8  17  10  1  3 
* CBA mice, after pretreatment with cyclophosphamide  (100 mg/kg) at various intervals earlier, were 
injected with 2  x  10  ~ BALB/e(H.2 ~) spleen cells into the hind foot pad. 4 days later the draining LNs 
were removed and the cells were tested for cytotoxic activity against P815 (1"1-2  ~) and EL 4 (H-2  b) target 
cells at an effector to target cell ratio of 50:1 and 5:1. Assay time of the ~ZCr test was 3 h, background 
lysis of the targets was less than 13%. 
TABLe. III 
Effect of  Syngeneic Lymphocyte Transfer to Cyclophosphamide-Treated Mice 
on the Capacity to Generate in Vivo TNP-Specific CTL * 
C3H cells used for i.v. reconstitutien of cyclophos- 
phamide-treatad mice 
Cytotoxic activity of C3H LN cells 
% Specific lysis of TNP-cenjugated C3H targets 
30:15  5:1~ 
No cells  45  21 
Cortison-resistant  (i00  x  10  ~) thymocytes  19  5 
Bone marrow (20  x  10  ~)  40  18 
Spleen (50  ×  108)  8  -1 
Spleen, nylon (50 ×  10  s) fiber passed  13  2 
Spleen treated with (50  ×  10  s) anti-Thy 1.2 plus C  41  17 
nu]nu spleen (50  x  10  a)  43  20 
* C3H mice were treated  i.p.  with one dose of cyclophosphamide  (100 mg/kg). 48 h  later,  the mice were first 
injected intravenously with the ee]l pepulatious  listed and then injected with 2  ×  107 TNP-conjugated C3H 
spleen cells into the hind foot pad. 4 days later the draining LNs were removed and the cells were tested for 
cytotogic activity against TNP-oonjugated LPS-induced syngeneic blast cells. Assay time of the SZCr  test was 3 
h, background lysis of the targets was less t}mn 19%. 
Ratio effector cells to target cells. 
lymphocytes, cyclophosphamide-treated  mice, simultaneously with the immuni- 
zation with TNP-conjugated stimulator spleen cells, were also "reconstituted" 
with  grafts to  various  cell types derived from normal syngeneic mice.  The 
results given in Table III indicate that B lymphocytes did not influence the 
differentiation  of CTL in cyclophosphamide-treated  mice. However, transfer of T 
cells from normal  CBA  mice abolished  the  cyclophosphamide-induced CTL- 
augmenting effect. 
Discussion 
The new aspect of the experiments described consists in the observation that 
cyclophosphamide treatment of mice before immunization with cell-bound anti- 
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antigen-specific CTL.  This refers to T-cell-mediated in vivo cytotoxic allograft 
responses,  and  in  particular  to  H-2-restricted in  vivo  cytotoxic anti-hapten 
responses. In the latter system it has been proven difficult to induce in vivo CTL 
(4,  5).  Therefore, from an operational point of view, cyclophosphamide treat- 
ment of mice results in a conversion of their in vivo state of low responsiveness 
into a state of high responsiveness. This conversion can again be reverted back 
to a state of low responsiveness by reconstituting the cyclophosphamide-treated 
mice with normal T cells, suggesting that the in Vivo effect of cyclophosphamide 
operates on the level of T cells. From that it follows that in vivo cyclophospha- 
mide-sensitive  T  cells  suppress  the  in  vivo  generation  of alloimmune  and 
hapten-immune cytotoxic T-effector cells. 
It  is  known that  in  vitro  sensitization  of murine T  lymphocytes towards 
alloantigens or hapten-conjugated syngeneic lymphocytes results in the genera- 
tion of highly effective CTL (1-3). Consequently the observed in vivo state of low 
responsiveness cannot be explained by a lack of antigen-reactive T cells with the 
appropriate  specificities.  Moreover,  recently  we  noted  that  T  cells  of mice 
sensitized in vivo, but incapable to differentiate into CTL, differentiate in CTL 
after transfer in vitro (6). These results suggest that the observed state of in vivo 
low responsiveness is neither due to a  lack of antigen recognition nor antigen 
processing through macrophages, but rather due to an inability of CTL precur- 
sors to differentiate in vivo into effective CTL. Since the results described here 
suggest that the in vivo blocked differentiation pathway of CTL can be overcome 
by pretreatment of mice with cyclophosphamide, and since this effect in turn can 
be neutralized by normal T cells, cyclophosphamide-sensitive suppressor T cells 
most likely block in vivo the final antigen-independent phase of the differentia- 
tion pathway of CTL. 
The immune response augmenting effect of cyclophosphamide appears not to 
be restricted to the in vivo differentiation of CTL. For example, Lagrange et al. 
have found that  cyclophosphamide-potentiated T-cell-dependent delayed-type 
hypersensitivity (DTH) to sheep erythrocytes (SRBC)  (I0).  More recently As- 
kenase et al. provided evidence that the augmenting effect of cyclophosphamide 
on  DTH  to  SRBC  is  due  to  the  inactivation  of cyclophosphamide-sensitive 
suppressor T  cells, which do not effect antibody responses (11).  Furthermore 
Miller et al. have demonstrated in the DTH system (12), and Debr~ et al. in the 
T-helper cell system (13) that low responsiveness of mice to antigens, which are 
under Ir-gene control,  can be overcome by cyclophosphamide. These reports 
together with the data presented here, favor the concept that the T-cell immune 
responsiveness in  vivo  against  a  variety of antigens is  under the control of 
cyclophosphamide-sensitive suppressor T cells. 
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